Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003

Description

N/A

Inclusion Criteria:
Subjects having participated in the SC Treatment Period of pivotal study IgPro20_3003 (NCT01545076).
Written informed consent for study participation obtained before undergoing any study-specific procedures.
If treatment for CIDP is required, it has to include Immunoglobulin G (IgGs).
Subjects who completed study IgPro20_3003 before study IgPro20_3004 study was open for enrollment at the site must be enrolled no later than 8 weeks after study IgPro20_3004 is open for enrollment at the site.
Subjects who completed study IgPro20_3003 after study IgPro20_3004 study was open for enrollment at the site must be enrolled no later than 8 weeks after the completion visit of study IgPro20_3003. Exclusion Criteria:
Any polyneuropathy of other causes
Any other disease (mainly neurological or chronic orthopedic) that has caused neurological symptoms or may interfere with treatment or outcome assessments
Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study
History of thrombotic episodes within the 2 years prior to enrolment
Known allergic or other severe reactions to blood products including intolerability to previous IVIG (normal human immunoglobulin for intravenous administration) and/or SCIG (subcutaneous immunoglobulin)

Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.